Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer study responded to its treatment.

Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal worth up to $5.7bn. The agreement will see Novartis pay ...

BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

As of Wednesday, December 24, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 5.10%, which has investors questioning if this is right time to sell.

Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) climbed about 3.5% after the company released encouraging interim results from its Phase 1/2 clinical trial evaluating MRT-2359 alongside enzalutamide ...

Monte Rosa Therapeutics is at it again, banking $95 million just six months after reeling in a $96 million series B. The funds will propel the company’s lead protein-degrading program into the clinic ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Monte Rosa Therapeutics' shares have surged after a recent $150 million partnership with Novartis, which helped validate its molecular glue degrader (MGD) approach despite limited clinical results.

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company developing small molecules to degrade disease-related proteins, today exited stealth mode revealing a $32 ...

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, announced today the closing of a Series B ...

A Spanish climber has died and four others were injured when a cornice beneath them collapsed in the Alps. The accident happened on Castor Peak in the Monte Rosa massif, situated between Italy and ...